Parkinson's Study Revives Hopes of Neuronal Recovery
Scientists at Stanford University have demonstrated that suppressing the hyperactivity of a specific enzyme, LRRK2, with a compound called MLi-2 can prompt substantial recovery of dopaminergic signalling in a genetically engineered mouse model of Parkinson's. The treatment not only halted further degeneration but appeared to reverse structural impairments in the affected brain cells, marking a significant shift in understanding how Parkinson's progression might be modified at a cellular level.
Parkinson's, a neurodegenerative condition marked by tremors, rigidity, and impaired movement, is primarily caused by the death of dopamine-producing neurons in the brain's substantia nigra. For decades, treatments have largely focused on symptom management rather than tackling the root causes of cellular dysfunction. The Stanford findings now suggest that correcting underlying molecular defects could pave the way for regenerative strategies.
ADVERTISEMENT
The breakthrough centres on the LRRK2 enzyme, mutations in which are among the most common genetic causes of Parkinson's. Overactive LRRK2 has been linked to damage of cellular structures called primary cilia — antenna-like projections that play a vital role in neuron communication and survival. The research team found that neurons in the striatum of the brain — a key region involved in motor control — lacked these cilia in the Parkinson's model mice.
Using the LRRK2-inhibiting compound MLi-2, the team observed a significant regeneration of these lost cilia after three months of treatment. Dopamine signals began to function normally again in many of the affected neurons. The mice showed molecular signs of cellular recovery, with restored receptor localisation and improved intercellular communication. Importantly, the drug was administered after symptoms had started to appear, indicating that early-stage intervention could potentially reverse some aspects of the disease.
Further investigations revealed that the repaired cilia helped restore the sonic hedgehog signalling pathway, which is essential for neuron protection and maintenance. In Parkinson's, reduced Shh signalling due to cilia loss contributes to further deterioration of neurons. Restoring this pathway through cilia regrowth suggests a dual benefit: halting ongoing degeneration and triggering repair mechanisms.
Although the research was conducted on genetically modified mice, the implications for human forms of Parkinson's could be significant. LRRK2 mutations account for a relatively small percentage of all Parkinson's cases, but the pathway affected by this mutation may play a broader role in other forms of the disease, including idiopathic Parkinson's with unknown genetic causes.
The MLi-2 compound itself is a highly selective, brain-penetrant molecule designed to inhibit LRRK2 activity without causing off-target effects. Previous efforts to target LRRK2 were hindered by concerns over safety and unintended consequences in other organs where the enzyme is also active. However, the current study found no major toxic effects over the duration of the experiment, opening the door for cautious optimism about its translational potential.
ADVERTISEMENT
Neuroscientists have long been searching for ways to go beyond dopamine replacement therapies, which offer temporary relief but do not prevent neuron loss. Deep brain stimulation and other invasive procedures are used in advanced cases but are not curative. A pharmacological approach that addresses root biological causes has remained elusive. The discovery that cellular antennae can regrow and restore critical signalling functions represents a conceptual leap in the field.
Experts have noted that early intervention will be key. While the drug showed promise after symptoms appeared, the degree of neuronal recovery is likely to depend on how much degeneration has already taken place. Identifying Parkinson's earlier in its course, perhaps through biomarker detection, may significantly enhance the efficacy of such treatments.
Further preclinical studies and safety evaluations are expected before MLi-2 or similar compounds move into human trials. Nonetheless, the research has sparked considerable interest among those exploring disease-modifying treatments. If replicated and expanded, the findings could contribute to a paradigm shift in the management of neurodegenerative conditions more broadly.
The concept of regrowing cilia to restore function in damaged neurons could also have implications for other central nervous system disorders involving disrupted cell signalling. Beyond Parkinson's, researchers are already examining cilia dysfunction in conditions such as Alzheimer's and Huntington's disease.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Today
4 days ago
- Gulf Today
Researchers develop new tool to measure biological age
Andrew Zeng, Tribune News Service Researchers at Stanford University have developed a new tool that can compute the 'biological age' of human organs by processing a single vial of blood. The tool, unveiled in Nature Medicine Wednesday morning, was developed by a research team spearheaded by Tony Wyss-Coray. Wyss-Coray, a Stanford Medicine professor who has spent almost 15 years fixated on the study of aging, said that the tool could 'change our approach to health care.' 'It could help us shift from sick care to health care, and empower people to take care of their own body,' he said. Scouring a single draw of blood for thousands of proteins, the tool works by first comparing the levels of these proteins with their average levels at a given age. An artificial intelligence algorithm then uses these gaps to derive a 'biological age' for each organ. To test the accuracy of these 'biological ages,' the researchers processed data for 45,000 people from the UK Biobank, a database that has kept detailed health information from over half a million British citizens for the last 17 years. When they analysed the data, the researchers found a clear trend for all 11 organs they studied; biologically older organs were significantly more likely to develop aging-related diseases than younger ones. For instance, those with older hearts were at much higher risk for atrial fibrillation or heart failure, while those with older lungs were much more likely to develop chronic obstructive pulmonary disease. But the brain's biological age, Wyss-Coray said, was 'particularly important in determining or predicting how long you're going to live.' 'If you have a very young brain, those people live the longest,' he said. 'If you have a very old brain, those people are going to die the soonest out of all the organs we looked at.' Indeed, for a given chronological age, those with 'extremely aged brains' — the 7% whose brains scored the highest on biological age — were over 12 times more likely to develop Alzheimer's disease over the next decade than those with 'extremely youthful brains' — the 7% whose brains inhabited the other end of the spectrum. Wyss-Coray's team also found several factors — smoking, alcohol, poverty, insomnia and processed meat consumption — were directly correlated with biologically aged organs. Poultry consumption, vigorous exercise, and oily fish consumption were among the factors correlated with biologically youthful organs. Supplements like glucosamine and estrogen replacements also seemed to have 'protective effects,' Wyss-Coray said. With these results, Wyss-Coray's team set about testing the tool on people in real time. The fifth person they tested was Paul Coletta, an entrepreneur who decided to participate in the test after reading a preliminary Nature paper that had been sent by a friend. The test found that Coletta, then 60, had kidneys that were biologically 68 years old. 'My GFR, my creatinine, all the typical kidney biomarkers came back as normal, but I followed up with an ultrasound, and it revealed a large renal cyst in my left kidney,' he said. 'It found an early signal of decline, and it empowered me to act.' Coletta was so impressed that he agreed to found Vero Bioscience, a company that now has an exclusive license from Stanford Medicine to commercialize the product, with Wyss-Coray. Coletta said he planned to make the tool the core of an 'at-home AI health clinic.' 'It's not just a kit where you send us your blood and you get a result,' he said. 'We want to support the consumer through the journey of what the intervention should be for that organ, interpreting the results and then retesting to see if there was a reversal in the organ age.' The test, Coletta said, would cost $200 once it could be operated at scale. Malia Fullerton, a professor of bioethics and humanities at the University of Washington, said that while the tool 'seems very promising as a global technique,' there were several ethical concerns when it came to its application. 'I could imagine for folks who are interested in being super agers, a desire to get rid of their quickly aging organs and replace them with new ones,' she said. 'I see the first negative consequence — particularly if this goes directly to consumer — being putting strains on our organ donation system, which is already under complete duress.' Overall, Fullerton said, 'the question your readers could ask themselves is: Is human lifespan, and is human quality of life merely a function of the health of our organs, or is there some higher-order set of interactions here that are not being captured in this kind of analysis?' Wyss-Coray said the risks of an organ transplant currently far outweighed the potential reward of replacing an aged organ with a healthy one, particularly since the test was merely a risk assessment. In any case, he said, it would be challenging to solve the issue completely.
Arabian Post
05-07-2025
- Arabian Post
Parkinson's Study Revives Hopes of Neuronal Recovery
A targeted drug therapy has shown potential to reverse cellular damage in Parkinson's disease by regenerating critical brain structures and restoring neuron function, according to new findings from a leading neuroscience research team. Scientists at Stanford University have demonstrated that suppressing the hyperactivity of a specific enzyme, LRRK2, with a compound called MLi-2 can prompt substantial recovery of dopaminergic signalling in a genetically engineered mouse model of Parkinson's. The treatment not only halted further degeneration but appeared to reverse structural impairments in the affected brain cells, marking a significant shift in understanding how Parkinson's progression might be modified at a cellular level. Parkinson's, a neurodegenerative condition marked by tremors, rigidity, and impaired movement, is primarily caused by the death of dopamine-producing neurons in the brain's substantia nigra. For decades, treatments have largely focused on symptom management rather than tackling the root causes of cellular dysfunction. The Stanford findings now suggest that correcting underlying molecular defects could pave the way for regenerative strategies. ADVERTISEMENT The breakthrough centres on the LRRK2 enzyme, mutations in which are among the most common genetic causes of Parkinson's. Overactive LRRK2 has been linked to damage of cellular structures called primary cilia — antenna-like projections that play a vital role in neuron communication and survival. The research team found that neurons in the striatum of the brain — a key region involved in motor control — lacked these cilia in the Parkinson's model mice. Using the LRRK2-inhibiting compound MLi-2, the team observed a significant regeneration of these lost cilia after three months of treatment. Dopamine signals began to function normally again in many of the affected neurons. The mice showed molecular signs of cellular recovery, with restored receptor localisation and improved intercellular communication. Importantly, the drug was administered after symptoms had started to appear, indicating that early-stage intervention could potentially reverse some aspects of the disease. Further investigations revealed that the repaired cilia helped restore the sonic hedgehog signalling pathway, which is essential for neuron protection and maintenance. In Parkinson's, reduced Shh signalling due to cilia loss contributes to further deterioration of neurons. Restoring this pathway through cilia regrowth suggests a dual benefit: halting ongoing degeneration and triggering repair mechanisms. Although the research was conducted on genetically modified mice, the implications for human forms of Parkinson's could be significant. LRRK2 mutations account for a relatively small percentage of all Parkinson's cases, but the pathway affected by this mutation may play a broader role in other forms of the disease, including idiopathic Parkinson's with unknown genetic causes. The MLi-2 compound itself is a highly selective, brain-penetrant molecule designed to inhibit LRRK2 activity without causing off-target effects. Previous efforts to target LRRK2 were hindered by concerns over safety and unintended consequences in other organs where the enzyme is also active. However, the current study found no major toxic effects over the duration of the experiment, opening the door for cautious optimism about its translational potential. ADVERTISEMENT Neuroscientists have long been searching for ways to go beyond dopamine replacement therapies, which offer temporary relief but do not prevent neuron loss. Deep brain stimulation and other invasive procedures are used in advanced cases but are not curative. A pharmacological approach that addresses root biological causes has remained elusive. The discovery that cellular antennae can regrow and restore critical signalling functions represents a conceptual leap in the field. Experts have noted that early intervention will be key. While the drug showed promise after symptoms appeared, the degree of neuronal recovery is likely to depend on how much degeneration has already taken place. Identifying Parkinson's earlier in its course, perhaps through biomarker detection, may significantly enhance the efficacy of such treatments. Further preclinical studies and safety evaluations are expected before MLi-2 or similar compounds move into human trials. Nonetheless, the research has sparked considerable interest among those exploring disease-modifying treatments. If replicated and expanded, the findings could contribute to a paradigm shift in the management of neurodegenerative conditions more broadly. The concept of regrowing cilia to restore function in damaged neurons could also have implications for other central nervous system disorders involving disrupted cell signalling. Beyond Parkinson's, researchers are already examining cilia dysfunction in conditions such as Alzheimer's and Huntington's disease.
Gulf Today
27-06-2025
- Gulf Today
Farewell to the US as the world's top science nation
Llewellyn King, Tribune News Service When I asked John Savage, the retired co-founder of the Department of Computer Science at Brown University, what the essential ingredient in research is, he responded with one word: 'Passion.' It is passion that keeps scientists going, dead end after dead end, until there is a breakthrough. It is passion that keeps them at the bench or staring into a microscope or redesigning an experiment with slight modifications until that 'eureka moment.' I have been writing about science for half a century. I can tell you that passion is the bridge between daunting difficulty and triumphant discovery. Next comes money: steady, reliable funding, not start-and-stop dribbles. It is painful to watch the defunding of the nation's research arm by a third to a half, the wanton destruction of what, since the end of World War II, has kept the United States the premier inventor nation, the unequaled leader in discovery. It is dangerous to believe the status quo ante will return when another administration is voted in, maybe in 2028. You don't pick up the pieces of projects that are, as they were, ripped from the womb and put them back together again, even if the researchers are still available — if they haven't gone to the willing arms of research hubs overseas or other careers. The work isn't made whole again just because the money is back. The passion is gone. There are crude, massive reductions in funding for research and development across the government — with the most axing in the National Institutes of Health, the National Science Foundation and the Department of Energy. The Philistines, with their metaphorical chainsaws, have slashed wildly and deeply into every corner of science, every place where talented men and women probe, analyze and seek to know. This brutal, mindless slashing isn't just upending careers, causing projects to be abandoned in midstream and destroying the precious passion that drives discovery, but it is also a blow against the future. It is a turn from light to dark. The whiz kids of DOGE aren't cost-cutting; they are amputating the nation's future. The cutting of funds to NIH — until now the world's premier medical research center, a citadel of hope for the sick and the guarantor that the future will have less suffering than the past — may be the most egregious act of many. It is a terrible blow to those suffering from cancer to Parkinson's and the myriad diseases in between who hope that NIH will come up with a cure or a therapy before they die prematurely. It is a heartless betrayal. The full horror of the dismantling of what they call the nation's 'scientific pillar' has been laid out by two of America's most eminent scientists in an essay in the Bulletin of the Atomic Scientists. They are John Holdren, who served as President Barack Obama's science adviser and as director of the White House Office of Science and Technology Policy, and Neal Lane, who was President Bill Clinton's science adviser and is a former NSF director. In their alarming and telling essay, they appeal to Congress to step in and save America's global leadership in science. They write, 'What is happening now exceeds our worst fears. Consider, first, the National Science Foundation, one of the brightest jewels in the crown of U.S. science and the public interest. ... It's the nation's largest single funder of university basic research in fields other than medicine. Basic research, of course, is the seed corn from which future advances in applied science and technology flow.' The NSF co-stars in the federal research ecosystem with NIH and DOE, the authors write. The NSF has funded research underpinning the internet, the Google search engine, magnetic resonance imaging, laser eye surgery, 3-D printing, CRISPR gene editing technology and much more. The NIH is the world's leading biomedical research facility. The writers say it spends 83% of its $48 billion annual budget on competitive grants, supporting 300,000 researchers at more than 2,500 institutions in all 50 states. An additional 11% of the agency's budget supports the 6,000 researchers in its laboratories. Holdren and Lane write, 'Of the Energy Department's $50 billion budget in fiscal 2024, about $15 billion went to non-defense research and development.' Some $8 billion of this funding went to the DOE Office of Science Research, the largest funder of basic research in the physical sciences, supporting 300 institutions nationwide, including the department's 17 laboratories. In all of the seminal moves made by the Trump administration, what The Economist calls the president's 'War on Science' may be the most damaging.
